Cargando…

Cardiovascular toxicity from therapies for light chain amyloidosis

Amyloid light-chain (AL) amyloidosis is a hematological disorder characterized by abnormal proliferation of a plasma cell clone producing monoclonal free light chains that misfold and aggregate into insoluble fibrils in various tissues. Cardiac involvement is a common feature leading to restrictive...

Descripción completa

Detalles Bibliográficos
Autores principales:	Morfino, Paolo, Aimo, Alberto, Castiglione, Vincenzo, Chianca, Michela, Vergaro, Giuseppe, Cipolla, Carlo Maria, Fedele, Antonella, Emdin, Michele, Fabiani, Iacopo, Cardinale, Daniela
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Cardiovascular Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10354454/ https://www.ncbi.nlm.nih.gov/pubmed/37476571 http://dx.doi.org/10.3389/fcvm.2023.1212983

Ejemplares similares

Bidirectional Relationship Between Cancer and Heart Failure: Insights on Circulating Biomarkers
por: Chianca, Michela, et al.
Publicado: (2022)

Monoclonal antibodies and amyloid removal as a therapeutic strategy for cardiac amyloidosis
por: Emdin, Michele, et al.
Publicado: (2023)

Treatment Options in AF Patients with Cancer; Focus on Catheter Ablation
por: Garibaldi, Silvia, et al.
Publicado: (2022)

Biopsy Evidence of Sequential Transthyretin and Immunoglobulin Light-Chain Cardiac Amyloidosis in the Same Patient
por: Vergaro, Giuseppe, et al.
Publicado: (2021)

Biomarkers of HFpEF: Natriuretic Peptides, High-Sensitivity Troponins and Beyond
por: Morfino, Paolo, et al.
Publicado: (2022)

Atrial amyloidosis: mechanisms and clinical manifestations
por: Vergaro, Giuseppe, et al.
Publicado: (2022)

Prognostic value of soluble ST2 in AL and TTR cardiac amyloidosis: a multicenter study
por: Nicol, Martin, et al.
Publicado: (2023)

Transthyretin Stabilizers and Seeding Inhibitors as Therapies for Amyloid Transthyretin Cardiomyopathy
por: Morfino, Paolo, et al.
Publicado: (2023)

Valve disease in cardiac amyloidosis: an echocardiographic score
por: Aimo, Alberto, et al.
Publicado: (2023)

Amyloid seeding as a disease mechanism and treatment target in transthyretin cardiac amyloidosis
por: Morfino, Paolo, et al.
Publicado: (2022)

Tissue Characterization in Cardiac Amyloidosis
por: Musetti, Veronica, et al.
Publicado: (2022)

Abdominal Fat Biopsy for the Diagnosis of Cardiac Amyloidosis
por: Aimo, Alberto, et al.
Publicado: (2020)

Galectin-3 and Risk for Cancer or Heart Failure: Does Sex Matter?
por: Fabiani, Iacopo, et al.
Publicado: (2023)

Cardiotoxicity of Anthracyclines
por: Cardinale, Daniela, et al.
Publicado: (2020)

Treatment of cardiac fibrosis: from neuro-hormonal inhibitors to CAR-T cell therapy
por: Morfino, Paolo, et al.
Publicado: (2022)

The place of vericiguat in the landscape of treatment for heart failure with reduced ejection fraction
por: Aimo, Alberto, et al.
Publicado: (2021)

Biomarkers for the diagnosis and management of heart failure
por: Castiglione, Vincenzo, et al.
Publicado: (2021)

Oxidative stress and inflammation: determinants of anthracycline cardiotoxicity and possible therapeutic targets
por: Fabiani, Iacopo, et al.
Publicado: (2020)

Role of Imaging in Cardiomyopathies
por: Castiglione, Vincenzo, et al.
Publicado: (2023)

Redefining the epidemiology of cardiac amyloidosis. A systematic review and meta‐analysis of screening studies
por: Aimo, Alberto, et al.
Publicado: (2022)

Subclinical cardiac damage in cancer patients before chemotherapy
por: Fabiani, Iacopo, et al.
Publicado: (2021)

Deep learning to diagnose cardiac amyloidosis from cardiovascular magnetic resonance
por: Martini, Nicola, et al.
Publicado: (2020)

Risk Stratification in Transthyretin Cardiac Amyloidosis: The Added Value of Lung Spirometry
por: Banydeen, Rishika, et al.
Publicado: (2023)

Quality of life assessment in amyloid transthyretin (ATTR) amyloidosis
por: Aimo, Alberto, et al.
Publicado: (2021)

Thromboembolism and bleeding in systemic amyloidosis: a review
por: Nicol, Martin, et al.
Publicado: (2021)

The Journey of Human Transthyretin: Synthesis, Structure Stability, and Catabolism
por: Sanguinetti, Chiara, et al.
Publicado: (2022)

Pathophysiological Rationale and Clinical Evidence for Neurohormonal Modulation in Heart Failure with Preserved Ejection Fraction
por: Castiglione, Vincenzo, et al.
Publicado: (2023)

Safety and Efficacy of Amiodarone in a Patient With COVID-19
por: Castaldo, Nadia, et al.
Publicado: (2020)

Treating amyloid transthyretin cardiomyopathy: lessons learned from clinical trials
por: Tomasoni, Daniela, et al.
Publicado: (2023)

Current and emerging drug targets in heart failure treatment
por: Ghionzoli, Nicolò, et al.
Publicado: (2021)

Intact fibroblast growth factor 23 in heart failure with reduced and mildly reduced ejection fraction
por: Vergaro, Giuseppe, et al.
Publicado: (2023)

Prognostic Value of Circulating sST2 for the Prediction of Mortality in Patients With Cardiac Light-Chain Amyloidosis
por: Zhang, Yang, et al.
Publicado: (2021)

Grade 3 myocardial uptake in (99m)technetium-pyrophosphate scintigraphy in light chain cardiac amyloidosis
por: Okada, Atsushi, et al.
Publicado: (2021)

Electrocardiogram Characteristics and Prognostic Value in Light-Chain Amyloidosis: A Comparison With Cardiac Magnetic Resonance Imaging
por: Guo, Xinli, et al.
Publicado: (2021)

Light Chain Amyloidosis
por: Milani, Paolo, et al.
Publicado: (2018)

Prognostic Implication of Longitudinal Changes of Left Ventricular Global Strain After Chemotherapy in Cardiac Light Chain Amyloidosis
por: Bak, Minjung, et al.
Publicado: (2022)

Cardioncological Approach for Trastuzumab Therapy in Breast Cancer Patients With Cardiotoxicity: Impact on Adherence and Clinical Outcome
por: Fabiani, Iacopo, et al.
Publicado: (2020)

High Serum Carbohydrate Antigen (CA) 125 Level Is Associated With Poor Prognosis in Patients With Light-Chain Cardiac Amyloidosis
por: Li, Muzheng, et al.
Publicado: (2021)

A Risk Score to Diagnose Cardiac Involvement and Provide Prognosis Information in Patients at Risk of Cardiac Light-Chain Amyloidosis
por: Wu, Yan, et al.
Publicado: (2022)

Corrigendum: Prognostic implication of longitudinal changes of left ventricular global strain after chemotherapy in cardiac light chain amyloidosis
por: Bak, Minjung, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_gtbc0cg4kkmma9udt9m262la1j